Rojnic Kuzman Martina, Makaric Porin, Bosnjak Kuharic Dina, Kekin Ivana, Rossini Gajsak Linda, Boban Marina, Bozina Nada, Bozina Tamara, Celic Ruzic Mirela, Darmopil Sanja, Filipcic Igor, Ganoci Lana, Hladnik Ana, Madzarac Zoran, Malojcic Branko, Mihaljevic Peles Alma, Mueller Daniel J, Ostojic Drazenka, Petanjek Zdravko, Petrovic Ratimir, Vogrinc Zeljka, Savic Aleksandar, Silic Ante, Sagud Marina, Zivkovic Maja, Bajic Zarko
Department of Psychiatry, Zagreb University Hospital Centre, Kispaticeva 12, 10000 Zagreb, Croatia,
Psychiatr Danub. 2019 Jun;31(2):162-171. doi: 10.24869/psyd.2019.162.
In this project, we recruited a sample of 150 patients with first episode of psychosis with schizophrenia features (FEP) and 100 healthy controls. We assessed the differences between these two groups, as well as the changes between the acute phase of illness and subsequent remission among patients over 18-month longitudinal follow-up. The assessments were divided into four work packages (WP): WP1- psychopathological status, neurocognitive functioning and emotional recognition; WP2- stress response measured by saliva cortisol during a stress paradigm; cerebral blood perfusion in the resting state (with single photon emission computed tomography (SPECT) and during activation paradigm (with Transcranial Ultrasonography Doppler (TCD); WP3-post mortem analysis in histologically prepared human cortical tissue of post mortem samples of subjects with schizophrenia in the region that synaptic alteration was suggested by WP1 and WP2; WP4- pharmacogenetic analysis (single gene polymorphisms and genome wide association study (GWAS). We expect that the analysis of these data will identify a set of markers that differentiate healthy controls from patients with FEP, and serve as an additional diagnostic tool in the first episode of psychosis, and prediction tool which can be then used to help tailoring individualized treatment options. In this paper, we describe the project protocol including aims and methods and provide a brief description of planned post mortem studies and pharmacogenetic analysis.
在本项目中，我们招募了150例具有精神分裂症特征的首次发作精神病患者（FEP）样本以及100名健康对照者。我们评估了这两组之间的差异，以及在18个月的纵向随访中患者疾病急性期与随后缓解期之间的变化。评估分为四个工作包（WP）：WP1 - 精神病理状态、神经认知功能和情绪识别；WP2 - 在应激范式下通过唾液皮质醇测量应激反应；静息状态下的脑血流灌注（使用单光子发射计算机断层扫描（SPECT））以及激活范式下的脑血流灌注（使用经颅超声多普勒（TCD））；WP3 - 对WP1和WP2提示有突触改变区域的精神分裂症患者尸检样本的组织学制备的人类皮质组织进行尸检分析；WP4 - 药物遗传学分析（单基因多态性和全基因组关联研究（GWAS））。我们期望对这些数据的分析能够识别出一组可区分健康对照者与FEP患者的标志物，并作为精神病首次发作时的额外诊断工具以及预测工具，随后可用于帮助制定个体化治疗方案。在本文中，我们描述了项目方案，包括目的和方法，并简要介绍了计划中的尸检研究和药物遗传学分析。
